Pharma

Your Article Summary

See Latest Articles

Certolizumab pegol (Cimzia): Anti-TNF-alpha mAb approved for the treatment of rheumatoid arthritis
Formulary , 06/10/09

Tumor necrosis factor (TNF)-alpha is a proinflammatory cytokine that plays a key role in inflammatory processes. Certolizumab is a humanized monoclonal antibody (mAb) that neutralizes TNF-alpha. This agent was approved on May 2009, for the treatment of adults with moderately to severely active rheumatoid arthritis.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Abbott Seeks FDA Approval of New Dosage Strengths of SIMCOR
Abbott, 12/11/09

Recombinant Human Erythropoietin, Epogin Injection Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09

Synthon announces European approvals for Raloxifene
Synthon, 12/08/09

 See all of Drug/Product Approvals